We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients PR Newswire STOCKHOLM, Sept. 13, 2024 STOCKHOLM, Sept. 13, 2024 /PRNewswire/...
Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98% PR Newswire STOCKHOLM, June 24, 2024 STOCKHOLM, June 24, 2024...
MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication PR Newswire STOCKHOLM, Feb. 7, 2024 STOCKHOLM, Feb. 7, 2024 /PRNewswire/...
MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication PR Newswire STOCKHOLM, Feb. 7, 2024 STOCKHOLM, Feb. 7, 2024 /PRNewswire/...
MOB-015 is recommended for approval in EU: Moberg Pharma PR Newswire STOCKHOLM, June 28, 2023 STOCKHOLM, June 28, 2023 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) hereby announces that...
European marketing authorization application for MOB-015 submitted PR Newswire STOCKHOLM, March 28, 2022 STOCKHOLM, March 28, 2022 /PRNewswire/ -- Moberg Pharma AB (publ) have submitted its...
The Medical Products Agency in Sweden will be reference member state for Moberg Pharma's European registration application PR Newswire STOCKHOLM, Dec. 23, 2021 STOCKHOLM, Dec. 23, 2021...
Moberg Pharma receives approval from the EMA's Paediatric Committee PR Newswire STOCKHOLM, Sept. 22, 2021 STOCKHOLM, Sept. 22, 2021 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) today announces...
Moberg Pharmas Year-end report 2020 PR Newswire STOCKHOLM, Feb. 9, 2021 STOCKHOLM, Feb. 9, 2021 /PRNewswire/ -- Financing for both MOB-015 and BUPI PERIOD (JUL 2019-DEC 2020) Net...
Moberg Pharma: Announcement of terms for the fully guaranteed rights issue in OncoZenge, timetable for the listing and record date for Lex Asea PR Newswire STOCKHOLM, Jan. 29, 2021 STOCKHOLM...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions